【摘 要】
：
Drug-eluting stents (DES) are widely used for the treatment of coronary artery disease with benefit of reduced restenosis compared to bare metal stents.The XIENCE V(R) Everolimus Eluting Coronary Sten
【机 构】
：
Abbott Laboratories (Abbott Vascular)USA
【出 处】
：
BITs 2rd Annual World Cancer Congress of Cardiology-2010(201
论文部分内容阅读
Drug-eluting stents (DES) are widely used for the treatment of coronary artery disease with benefit of reduced restenosis compared to bare metal stents.The XIENCE V(R) Everolimus Eluting Coronary Stent System is a second generation DES system for better deliverability while maintaining safety and efficacy profiles.Everolimus delivered by the XIENCE V(R) stent is in the family of sirolimus which exerts its anti-proliferation of vascular smooth muscle cells through blocking the mTOR (mammalian target ofrapamycin) function.
其他文献
Human cholestcryl ester transfer protein (CETP), a hydrophobic glycoprotein (476 amino acids, ~74 kDa), mediates the transfer of cholesteryl ester (CE) from high-density lipoproteins (HDL) to apo-B co
Cyclooxygenase-2 (COX-2) inhibitor use for coronary artery bypass graft (CABG) postoperative pain has been linked to adverse cardiovascular outcomes.An FDA black-box warningon the use of all NSAIDs pe
Cardiac arrhythmias are a source of significant morbidity and mortality worldwide.Nowadays, their treatment is still based on drugs with limited efficacy and safety profile, mainly due to our lack of
It is well known that antagonists of mineralocorticoid receptor (MR), a classic steroid hormone receptor, are cardioprotective and anti-inflammatory.These effects can be independent of hyperaldosteron
Any incident with potential deleterious consequences occurring while treating a patient with a medical device concerned medical device vigilance.In Europe, as well as in other part of the world, direc
The World Survey of Cardiac Pacing and Cardioverter Defibrillators is compiled every 4 years with the most recent results being for the calendar year 2005 and demonstrating a significant worldwide inc
Pacing at the right ventricular apex (RVA) is associated with a higher risk of cardiac failure.Unfortunately little is known about alternative pacing or defibrillation sites.We are aiming alternative
Limiting unnecessary ventricular pacing (VP) in patients (pts) who receive a dual-chamber (DDD) pacemaker (PM)appears desirable.Programming long AV delays has serious limitations in that respect: long
Several clinical studies (e.g.Danish Ⅱ1,2, Danish Ⅱ3,4, DAVID5, MOST sub analysis) have shown that unnecessary chronic right ventricular pacing has detrimental effects such as atrial fibrillation, lef
Over the last decade, atrial fibrillation (AF) and heart failure (HF) have emerged as new epidemics.During the same period, there has been an increase in the use of implantable devices for cardiac pac